Literature DB >> 18403653

The obesity epidemic: pharmacological challenges.

Stephen R Bloom1, Francis P Kuhajda, Ismail Laher, Xavier Pi-Sunyer, Gabriele V Ronnett, Tricia M M Tan, David S Weigle.   

Abstract

Obesity, defined by a body mass index greater than 30kg/m(2), claims an increasing number of lives every year, underscoring a dire need for effective therapeutic interventions. The origins of the obesity epidemic are complex, but commonly cited factors include the large quantities of calorie-rich food that are readily accessible in modern society; eating habits adapted to fast-paced lifestyles; low levels of physical activity; and genetic programs that have evolved, especially in populations prone to famine, to favor the storage of excess calories (i.e., the thrifty-gene theory). It is estimated that more than thirty percent of adults, and about fifteen percent of juveniles, are obese. These high rates have led to dramatic increases in diseases such as type 2 diabetes, cardiovascular and respiratory diseases, depression, and some forms of cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18403653     DOI: 10.1124/mi.8.2.6

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  15 in total

1.  Obesity and vascular dysfunction: the fat-e of rich and poor.

Authors:  Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 2.  New central targets for the treatment of obesity.

Authors:  Bruce J Sargent; Nicholas A Moore
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

3.  Leisure-time physical activity does not fully explain the higher body mass index in irregular-shift workers.

Authors:  Elaine Cristina Marqueze; Melissa Araújo Ulhôa; Claudia Roberta Castro Moreno
Journal:  Int Arch Occup Environ Health       Date:  2013-02-23       Impact factor: 3.015

4.  The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.

Authors:  Lisa B Van Wagner; Mary E Rinella
Journal:  Therap Adv Gastroenterol       Date:  2011-07       Impact factor: 4.409

5.  Chronic angiotensin AT2R activation prevents high-fat diet-induced adiposity and obesity in female mice independent of estrogen.

Authors:  Sourashish Nag; Mohammad Azhar Khan; Preethi Samuel; Quaisar Ali; Tahir Hussain
Journal:  Metabolism       Date:  2015-03-14       Impact factor: 8.694

Review 6.  Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.

Authors:  Lance L Stein; Mamie H Dong; Rohit Loomba
Journal:  Adv Ther       Date:  2009-11-16       Impact factor: 3.845

7.  Liver fibrogenesis in non-alcoholic steatohepatitis.

Authors:  Zhaolian Bian; Xiong Ma
Journal:  Front Physiol       Date:  2012-07-11       Impact factor: 4.566

8.  Brain-gut-microbe communication in health and disease.

Authors:  Sue Grenham; Gerard Clarke; John F Cryan; Timothy G Dinan
Journal:  Front Physiol       Date:  2011-12-07       Impact factor: 4.566

9.  Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.

Authors:  Alessandro Pocai; Paul E Carrington; Jennifer R Adams; Michael Wright; George Eiermann; Lan Zhu; Xiaobing Du; Aleksandr Petrov; Michael E Lassman; Guoqiang Jiang; Franklin Liu; Corey Miller; Laurie M Tota; Gaochao Zhou; Xiaoping Zhang; Michael M Sountis; Alessia Santoprete; Elena Capito'; Gary G Chicchi; Nancy Thornberry; Elisabetta Bianchi; Antonello Pessi; Donald J Marsh; Ranabir SinhaRoy
Journal:  Diabetes       Date:  2009-07-14       Impact factor: 9.461

10.  Genetic variations in the serotoninergic system contribute to body-mass index in Chinese adolescents.

Authors:  Chunhui Chen; Wen Chen; Chuansheng Chen; Robert Moyzis; Qinghua He; Xuemei Lei; Jin Li; Yunxin Wang; Bin Liu; Daiming Xiu; Bi Zhu; Qi Dong
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.